Single application of high-intensity focused ultrasound as primary therapy of localized prostate cancer: Treatment-related predictors of biochemical outcomes

被引:6
|
作者
Pfeiffer, Dietrich [1 ]
Berger, Juergen [2 ]
Gross, Andreas [1 ]
机构
[1] Asklepios Hosp Hamburg Barmbek, Dept Urol, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Ctr Med Expt, Inst Med Biometry & Epidemiol, Hamburg, Germany
关键词
Prostate cancer; High-intensity focused ultrasound; Efficacy; Biochemical failure; Prostate edema; Patient movement;
D O I
10.1016/j.ajur.2014.08.009
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: Recent reports on high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer suggest that preoperative risk groups of tumor recurrence are strong predictors of oncological outcomes. The purpose of this study is to determine the prognostic significance of treatment-related factors in relation to patient characteristics for biochemical outcomes after HIFU. Methods: This retrospective single-center study included patients treated from December 2002 to December 2010 for localized prostate cancer with two generations of Ablatherm (R) HIFU devices (A1 and A2). All the patients underwent single HIFU treatment session under the concept of whole-gland therapy. Prostate surgery was performed before HIFU to downsize enlarged glands. Androgen deprivation therapy (ADT) was discontinued before HIFU. Biochemical failure (BCF) was defined as prostate specific antigen (PSA) nadir + 1.2 ng/mL (Stuttgart definition). Predictors of BCF were determined using Cox regression models. As covariates, patient-related factors (age, tumor characteristics, ADT) were compared with treatment-related factors (prostate volume, HIFU device generation, conduct of therapy, prostate edema, patient movement, anesthetic modalities). Results: Three hundred and twenty-three (98.8%) out of 327 consecutive patients were evaluable for BCF. Median (interquartile range) follow-up was 51.2 (36.6-80.4) months. The overall BCF-rate was 23.8%. In multivariate analyses, higher initial PSA-values (Hazard ratio [HR]: 1.03; p < 0.001) and higher D'Amico risk stages (HR: 3.45; p < 0.001) were patient-related predictors of BCF. Regarding treatment-related factors, the A2 HIFU device was associated with a decreased risk of BCF (HR: 0.51; p Z 0.007), while prostate edema had an adverse effect HR: 1.8; p Z 0.027). Short follow-up and retrospective study design are the primary limitations. Conclusion: Success in a single HIFU session depends not merely on tumor characteristics, but also on treatment-related factors. Ablation is more efficacious with the technically advanced A2 HIFU device. Heat-induced prostate edema might adversely affect the outcome. (C) 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier ( Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license
引用
收藏
页码:46 / 52
页数:7
相关论文
共 50 条
  • [31] Urethra-sparing high-intensity focused ultrasound for localized prostate cancer: Functional and oncological outcomes
    Shoji, Sunao
    Nakano, Mayura
    Fujikawa, Hiroshi
    Endo, Kazuyuki
    Hashimoto, Akio
    Tomonaga, Tetsuro
    Terachi, Toshiro
    Uchida, Toyoaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (11) : 1043 - 1049
  • [32] High-intensity focused ultrasound therapy for pancreatic cancer
    Sofuni, Atsushi
    Asai, Yasutsugu
    Mukai, Shuntaro
    Yamamoto, Kenjiro
    Itoi, Takao
    JOURNAL OF MEDICAL ULTRASONICS, 2022,
  • [33] Results of low threshold to biopsy following high-intensity focused ultrasound for localized prostate cancer
    Haddad, Richard L.
    Hossack, Tania A.
    Woo, Henry H.
    UROLOGY ANNALS, 2012, 4 (02) : 84 - 88
  • [34] High-intensity focused ultrasound strategies for treating prostate cancer
    Wu, Xiaobo
    Wu, Yupeng
    Ng, Chi-Fai
    Yee, Chi-Hang
    Chiu, Peter Ka-Fung
    ASIAN JOURNAL OF ANDROLOGY, 2024, 26 (06): : 595 - 599
  • [35] High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer
    Cordeiro, Ernesto R.
    Cathelineau, Xavier
    Thueroff, Stefan
    Marberger, Michael
    Crouzet, Sebastien
    de la Rosette, Jean J. M. C. H.
    BJU INTERNATIONAL, 2012, 110 (09) : 1228 - 1242
  • [36] Histotripsy: The Next Generation of High-Intensity Focused Ultrasound for Focal Prostate Cancer Therapy
    Dubinsky, Theodore J.
    Khokhlova, Tanya D.
    Khokhlova, Vera
    Schade, George A.
    JOURNAL OF ULTRASOUND IN MEDICINE, 2020, 39 (06) : 1057 - 1067
  • [37] Usefulness of proton magnetic resonance spectroscopy in predicting positive biopsy after high-intensity focused ultrasound for treatment of localized prostate cancer
    Muto, Satoru
    Kaminaga, Tatsuro
    Horiuchi, Akira
    Kitamura, Kousuke
    Saito, Keisuke
    Isotani, Shuji
    Yamaguchi, Raizo
    Ide, Hisamitsu
    Furui, Shigeru
    Horie, Shigeo
    INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (08) : 776 - 780
  • [38] Twelve Years' Experience with High-Intensity Focused Ultrasound (HIFU) Using Sonablate™ Devices for the Treatment of Localized Prostate Cancer
    Uchida, Toyoaki
    Nakano, Muyura
    Shoji, Sunao
    Nagata, Yoshihiro
    Usui, Yukio
    Terachi, Toshiro
    11TH INTERNATIONAL SYMPOSIUM ON THERAPEUTIC ULTRASOUND, 2012, 1481 : 401 - 406
  • [39] Transurethral resection of the prostate immediately after high-intensity focused ultrasound treatment for prostate cancer
    Sumitomo, Makoto
    Asakuma, Junichi
    Sato, Akinori
    Ito, Keiichi
    Nagakura, Kazuhiko
    Asano, Tomohiko
    INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 (11) : 924 - 930
  • [40] Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer
    Uchida, T
    Ohkusa, H
    Yamashita, H
    Shoji, S
    Nagata, Y
    Hyodo, T
    Satoh, T
    INTERNATIONAL JOURNAL OF UROLOGY, 2006, 13 (03) : 228 - 233